Abstract
Background: Few studies have investigated the natural history of TaG1 urothelial carcinoma of the bladder (UCB). Objective: To assess the long-term outcomes of patients with TaG1 UCB and the impact of immediate postoperative instillation of chemotherapy (IPIC).
Design, setting, and participants: A retrospective analysis of 1447 patients with TaG1 UCB treated between 1996 and 2007 at eight centers. Median follow-up was 67.2 mo (interquartile range: 67.9).
Patients were stratified into three European Association of Urology (EAU) guidelines risk categories; high-risk patients (n = 11) were excluded. Intervention: Transurethral resection of the bladder with or without IPIC.
Outcome measurements and statistical analysis: Univariable and multivariable Cox regression models addressed factors associated with disease recurrence, disease progression, death of disease, and any-cause death. Results and limitations: Of the 1436 patients, 601 (41.9%) and 835 (58.1%) were assigned to low-and intermediate-risk categories, respectively.
The actuarial estimate of 5-yr recurrence-free survival was 56% (standard error: +/- 1). Advancing age (p = 0.04), tumor > 3 cm (p = 0.001), multiple tumors (p < 0.001), and recurrent tumors (p < 0.001) were independently associated with increased risk of disease recurrence, whereas IPIC was associated with decreased risk (p = 0.001).
The actuarial estimate of 5-yr progression-free survival was 95% +/- 1. Advancing age (p < 0.001) and multiple tumors (p = 0.01) were independent risk factors for disease progression.
Five-year cancer-specific survival was 98% +/- 1. Advancing age (p = 0.001) and previous recurrence (p = 0.04) were associated with increased risk, whereas female gender (p = 0.02) was associated with decreased risk of cancer-specific mortality.